BSEBoard Meeting4d ago · 14 Nov 2026, 03:52 pm
The Board of Directors considered and adopted the unaudited financial results for the quarter ended September 30, 2026
Samrat Pharmachem Ltd-$ · 530125
✦ AI SummaryResults
Samrat Pharmachem Ltd has announced its unaudited financial results for the quarter ended September 30, 2026, with a profit before tax of ₹4.34 lakhs and a profit for the year of ₹4.11 lakhs. The company's total assets stood at ₹13,133.87 lakhs, with equity of ₹6,949.63 lakhs and liabilities of ₹6,184.24 lakhs.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th November 2026
Attachments (1)
📄pdf
Download →
b0d4823e-42ed-4238-a2bf-c138770b0608.pdf
View document text
Regd. Office & Factory Corporate Office
Plot No. A2/3444-3445, GIDC, 701/702, Business Square,
Phase 4, Ankleshwar – 393 002 M.A. Road, Andheri (West),
Gujarat, India Mumbai – 400 058, India
Tel : +91-7045456789 / 7046456789 Tel : +91-7507534567 / 8760345678
Web: www.samratpharmachem.com CIN: L24230GJ1992PLC017820 Email: contact@samratpharmachem.in
November 14, 2026
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 530125
Dear Sir,
Sub: Outcome of the Board Meeting of the Company held today
We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday,
November 14, 2026, the Board has considered and took on record the attached Un-Audited Standalone
Financial Results of the Company for the quarter ended September 30, 2026, which is enclosed herewith along
with the Limited Review Report of the Statutory Auditor of the Company.
The meeting of the Board of Directors of the Company commenced at 14:00 hours and concluded at 15:30
hours.
Kindly inform all your members.
Thanking you,
Yours faithfully,
For Samrat Pharmachem Limited
Nishant Kankaria
Company Secretary & Compliance Officer
Samrat Pharmachem Limited
Regd Office : Plot No. A2/3444-3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)
Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)
Statement of standalone unaudited financial results for the quarter and half year ended September 30, 2026
(Currency : Indian Rupees in lakhs)
Quarter ended Half year ended Year ended
30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited)
A Continuing Operations
I INCOME
a) Revenue From Operations 6 ,600.86 7 ,976.10 7 ,887.03 1 4,576.96 1 5,452.19 2 8,972.12
b) Other Income 1 6.49 9 8.82 4 .81 1 15.31 7 3.94 8 3.37
Total Income 6 ,617.35 8 ,074.92 7 ,891.84 1 4,692.27 1 5,526.13 2 9,055.49
II EXPENSES
a) Cost of Material Consumed 6 ,566.40 7 ,830.88 7 ,333.35 1 4,397.28 1 5,585.06 2 8,966.68
b) Purchase of Traded Goods - - - - - -
c) Changes in inventories (237.05) (147.32) 3 81.20 (384.37) (531.51) (662.02)
d) Employee benefits expense 5 0.90 5 0.54 5 4.69 1 01.44 1 05.47 2 27.60
e) Finance costs 8 .00 1 1.38 2 5.53 1 9.38 6 9.32 9 5.53
f) Depreciation and amortisation expense 2 0.38 1 8.80 1 7.85 3 9.18 3 4.85 7 1.98
g) Other expenses 2 04.38 1 52.11 1 54.04 3 56.49 3 17.00 6 53.82
Total expenses 6 ,613.01 7 ,916.39 7 ,966.66 1 4,529.40 1 5,580.19 2 9,353.59
III Profit before tax before exceptional items (I - II) 4 .34 1 58.53 (74.82) 1 62.87 (54.06) (298.10)
IV Exceptional item income - - - - - -
Profit before tax after exceptional items (III + IV) 4 .34 1 58.53 (74.82) 1 62.87 (54.06) (298.10)
VI Tax expense
a) Current tax 6 .00 1 9.00 - 2 5.00 - 0 .09
b) Deferred tax (45.77) 5 1.94 (16.18) 6 .17 2 7.40 3 0.05
c) Short / (Excess) provision for tax - prior years - (0.01) 0 .07 (0.01) 0 .16 2 .96
Total Tax (39.77) 7 0.93 (16.11) 3 1.16 2 7.56 3 3.10
VII Profit for the year (V - VI) 4 4.11 8 7.60 (58.71) 1 31.71 (81.62) (331.20)
VIII Other Comprehensive Income
(a) Items that will not be reclassified to profit or loss
Remeasurement (losses) / gains on defined benefit obligations - - - - - -
(net)
Income tax on above credit / (charge) - - - - - -
Total (a) - - - - - -
(b) Items that will be reclassified to profit or loss
- - - - - -
Income tax on above credit / (charge) - - - - - -
Total (b) - - - - - -
Total other comprehensive (loss) / income - - - - - -
IX Total Comprehensive Income for the year (VII + VIII) 4 4.11 8 7.60 (58.71) 1 31.71 (81.62) (331.20)
X Basic and diluted earnings per equity share in Rupees 1 .43 2 .84 (1.90) 4 .26 (2.64) (10.72)
(Face value Rs. 10 each) *
* Not annualised for period less than one year
Notes:
1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Saturday,
November 14, 2026 at the Corporate Office of the Company.
3. The Company manufactures pharmaceutical chemicals, which is a single business segment.
4. The figures for the previous period have been regrouped where necessary to conform to current period's
classification.
By order of the Board of Directors
For Samrat Pharmachem Limited
Place: Mumbai
Date: November 14, 2026
Rajesh Mehta
Executive Director
DIN: 00216731
Statement of Assets & Liabilities as at September 30, 2026
(Currency : Indian Rupees in lakhs)
Particulars As at As at
30-Sep-26 31-Mar-26
(Unudited) (Audited)
ASSETS
I Non Current assets
a) Property, Plant and Equipment 1,381.13 1,170.25
Capital work-in-progress - 112.31
b) Other Intangible assets 1.09 1.21
c) Financial Assets
i) Investments 430.51 350.33
ii) Loans 32.17 31.09
iii) Other financial assets 407.10 397.70
d) Deferred tax assets (net) - -
d) Other non-current assets 46.29 -
2,298.29 2,062.89
IICurrent assets
a) Inventories 5,034.69 4,362.27
b) Financial Assets
i) Investments 41.56 36.78
ii) Trade receivables 5,120.45 5,104.81
iii) Cash and cash equivalents 599.63 588.24
iv) Other Bank balances 11.50 11.50
v) Loans - -
vi) Other financial assets 0.01 1.70
c) Other current assets 2 7.74 273.38
10,835.58 10,378.68
Total Assets 13,133.87 12,441.57
EQUITY AND LIABILITIES
I Equity
a) Equity Share capital 308.97 308.97
b) Other Equity 6,640.66 6,508.95
Total Equity 6,949.63 6,817.92
IILIABILITIES
A Non-current liabilities
a) Financial Liabilities
i) Borrowings - -
ii) Trade payables
Total outstanding dues of micro and small enterprises - -
Total outstanding dues of creditors other than micro and small enterprises - -
iii) Others - -
b) Provisions - -
c) Deferred tax liabilities (Net) 47.33 41.16
d) Other non-current liabilities - -
47.33 41.16
B Current liabilities
a) Financial Liabilities
i) Short term Borrowings 1,690.52 1,070.73
ii) Trade payables
Total outstanding dues of micro and small enterprises - -
Total outstanding dues of creditors other than micro and small enterprises 4,309.62 4,266.43
iii) Others 136.77 16.84
b) Provisions - -
c) Current Tax Liabilities (Net) - -
d) Other current liabilities - 228.49
6,136.91 5,582.49
Total Equity and Liabilities 13,133.87 12,441.57
Statement of cash flow
(Currency : Indian Rupees in lakhs)
Half year ended Half year ended
Particulars 30-Sep-26 30-Sep-25
(Unaudited) (Unaudited)
A Cash flow from operating activities
Profit Before Tax And Extraordinary Items 162.87 (54.06)
Adjustments for
Depreciation and amortisation 39.18 34.85
(Profit) / Loss on sale of Property, Plant and Equipments 2.30 -
(Profit) / Loss on sale of Investments (inluding fair value change) ( 101.45) (46.12)
Finance cost 19.38 69.32
Discount given / (received) (0.19) (0.57)
Dividend on investments (2.33) (2.10)
Interest income (9.12) (10.54)
Operating cash flow before working capital changes 110.64 (9.22)
Add / (Less): Adjustments for working capital changes
(Increase) / Decreasein Trade Receivables ( 15.45) 511.97
(Increase) / Decrease in Other Financial Assets (8.79) (2.46)
(Increase) / Decrease in Other non financial assets 189.81 612.79
(Increase) / Decrease in inventories ( 672.42) (70.00)
Increase / (Decrease) in other bank balances - (26.13)
Increase / (Decrease) in Trade payables 43.19 1,066.62
Increase / (Decrease) in Other financial liabilities 119.93 31.25
Increase / (Decrease) in Other non-financial liabilities ( 228.49) (0.22)
Increase / (Decrease) in Provisions - (2.49)
Cash used in operations ( 461.58) 2,112.11
Income taxes paid Income taxes paid (Net of Refunds Received) ( 15.45) ( 135.17)
Net cash used in operating activities -A ( 477.03) 1,976.94
B Cash flow from investing activities
Purchase of property, plant and equipment / capital work in progress ( 137.63) ( 142.44)
Sale of property, plant and equipment and intangible assets (2.30) -
Purchase of investments - ( 729.88)
Proceeds from sa
[Showing first 8,000 characters — download PDF for full document]